Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

sections

Category list : All-Wales Medicines Strategy Group

Sort by: Newest first Oldest first A-Z Z-A

  • Linaclotide (Constella; Almirall)

    Atomoxetine, abatacept, linaclotide and nalmefene recommended for use in Wales

    4 MAR 2014 16:21

    The All-Wales Medicines Strategy Group has endorsed atomoxetine, abatacept, linaclotide and nalmefene for use in NHS Wales in its latest round of medicines appraisals.

  • Lubiprostone

    New constipation drug gets a lukewarm response from DTB

    11 APR 2014 10:34

    Little published data on lubiprostone made it difficult to assess its efficacy, says the DTB

  • Revlar Ellipta approved for NHS use in Wales

    29 MAY 2014 15:16

    Inhaled fluticasone furoate and vilanterol (Relvar Ellipta) has been approved for use in NHS Wales by the All-Wales Medicines Strategy Group (AWMSG). it is recommended as an option for symptomatic treatment of adults with chronic obstructive pulmonary disease.

  • All Wales Medicines Strategy Group Subscription

    12 JUN 2014 8:51

    The following medicines have been approved for use in NHS Wales by the All Wales Medicines Strategy Group: Tocilizumab for juvenile idiopathic polyarthritis (rheumatoid factor positive or negative and extended oligoarthritis) in patients aged 2 years and older; Inhaled indacaterol/glycopyrronium as a maintenance bronchodilator in adults with chronic obstructive pulmonary disease; Tenofovir disoproxil film-coated tablets and granules to treat chronic hepatitis B in adults whose disease ...

  • AWMSG decisions Subscription

    5 AUG 2014 10:13

    The following medicines have been approved for use in NHS Wales by the All Wales Medicines Strategy Group (AWMSG): eltrombopag to treat thrombocytopenia in adults with hepatitis C infection where the degree of thrombocytopenia is compromising the efficacy of interferon; imatinib for adjuvent treatment of KIT-positive gastrointestinal stromal tumours; Eviplera (emtricitabine, rilpivirine and tenofovir; Gilead) for treatment-experienced adults infected with HIV type 1; and velaglucerase ...

  • AWMSG decisions Subscription

    18 AUG 2014 10:52

    The following medicines have been approved for use in NHS Wales by the All Wales Medicines Strategy Group (AWMSG): Aripiprazole prolonged release injection as maintenance treatment for schizophrenia in adults stabilised on oral aripiprazole Azithromycin infusion to treat community-acquired pneumonia where parenteral therapy is necessary (however, it should not be used to treat pelvic inflammatory disease) Delta-9-tetrahydrocannabinol (Sativex; GW Pharma) ...

  • Cannabis plant

    Cannabinoid Sativex approved in Wales to treat MS symptoms

    18 AUG 2014 15:17
    Comments (1)

    Wales has become the first country in the UK to approve the use of Sativex on the NHS to treat symptoms of multiple sclerosis.

  • Abraxane funded in Wales Subscription

    25 SEP 2014 10:18

    Patients with metastatic pancreatic cancer in Wales will have access to the drug Abraxane (paclitaxel; Celgene) on the NHS following a positive decision from the All Wales Medicines Strategy Group in September 2014. Wales is the only country in the UK where the chemotherapy drug will be routinely available to eligible patients on the NHS.

  • Dolutegravir approved in Wales Subscription

    25 SEP 2014 10:22

    Dolutegravir, in combination with other antiretrovirals, has been approved for use in NHS Wales by the All Wales Medicines Strategy Group to treat HIV infection in those aged 12 years and over.

  • AWMSG decisions Subscription

    2 OCT 2014 12:12

    The following medicines have not been recommended for use by the All Wales Medicines Strategy Group (AWMSG) and should not be prescribed in NHS Wales: Abiraterone (Zytiga) with prednisolone for metastatic castration-resistant prostate cancer in men who are asymptomatic or mildly symptomatic after androgen deprivation therapy (the drug is allowed for patients whose disease has progressed — as per National Institute ...

Show  10 per page20 per page50 per page

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.